{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoNnHuYgJDA","lastupdate":"2022-12-06T00:00:00.000Z","update_date":"2022-12-06T00:00:00.000Z","lastModified":"Oct 6, 2024","active":1,"confidence_score":90,"confidence_score_reason":"funding rounds, markets, not claimed","urlname":"wavelength-pharmaceuticals","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by SK Capital Partners on Nov, 2017","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$03aYlHjRBU2hrkeSJ5ZsXYyBC2W1QXMFJuvHD2MRn5b102S3UevBhK","name":"Wavelength Pharmaceuticals","oneliner":"Active Pharmaceutical Ingredients","registrar":"515666485","website":"https://www.wavelengthpharma.com","careerspage":"https://www.wavelengthpharma.com/careers","founded_month":1,"founded_year":1987,"formernames":["Chemagis","Perrigo API","Perrigo"],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/@wavelengthpharma5837","facebook":"https://www.facebook.com/wavelengthpharma","linkedin":"https://www.linkedin.com/company/35473024","instagram":""},"social":["https://www.youtube.com/@wavelengthpharma5837","https://www.facebook.com/wavelengthpharma","https://www.linkedin.com/company/35473024"],"flattenedsociallinks":"https://www.youtube.com/@wavelengthpharma5837|https://www.facebook.com/wavelengthpharma|https://www.linkedin.com/company/35473024","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":95,"patent":1,"raised":0,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Wave-length","Wave length","Wave.length"],"about":"Wavelength Pharmaceuticals develops and manufactures active pharmaceutical ingredients and select finished dosage forms.\r\n\r\nThe company focuses on differentiated products that require sophisticated manufacturing processes. Its solution provides customers with comprehensive technical support and in-depth regulatory support across the entire product lifecycle, from project inception to commercial production.\r\n\r\nWavelength Pharmaceuticals core strengths include complex chemistry, innovative process development, crystalline forms, and particle design. It tailors customized solutions to meet individual customer requirements, including full spectrum API CDMO services from preclinical grams to multi-ton commercial quantities.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97235773880","country":null,"address":{"israeli":[{"id":"3040ba10-1d7f-4942-8fab-0b890a49f2bf","city":"Ramat Hovav","type":null,"address":"Ramat Hovav, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null},{"id":"dfcec7c5-7a7d-4682-926c-45b0831a3870","city":"Petah Tikva","type":null,"address":"Shlomo Shmeltzer Road 94, Petah Tikva, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"083718ad-7b3b-4729-aa90-3e57faa719c0","city":"Barcelona","address":"Ronda del General Mitre, 126, Barcelona, Spain","country":"Spain","placeid":null},{"id":"b399d8aa-eedf-4dde-b7bd-7cf7a5241f1e","city":"Wayne","address":"1700 Route 23, Wayne, NJ 07470, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District,South District","news":[{"id":"uIDO2xU46z2u3JAczd0OMFiekWb9OCkS0J0QymmgpyTkp4npVMsjyc","date":"Sep 14, 2022","link":"https://www.prnewswire.com/news-releases/on-demand-pharmaceuticals-and-wavelength-pharmaceuticals-awarded-bird-foundation-grant-301624618.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"medicine manufacturing","company":"On Demand Pharmaceuticals, Inc.","layoffs":null,"summary":"On Demand Pharmaceuticals, Inc. (ODP) and Wavelength Pharmaceuticals are receiving a $1M investment from the US-Israel Binational Industrial Research & Development (BIRD) Foundation to advance on-demand, point-of-care medicine manufacturing. ODP and Wavelength Pharmaceuticals will leverage their manufacturing capabilities to strengthen the supply of essential medicines and their ingredients. The combination of their platforms aims to improve resource utilization and reduce cycle times in producing medicines. The current drug shortages, driven by economic crisis, global supply chain complexities, and pricing policies, pose a threat to public health. ODPs Pharmacy on Demand platform offers a rapid response capability to meet surges in demand and mitigate supply chain risks. The investment will support the development of a reliable supply of medicines.","partners":["Wavelength Pharmaceuticals"],"customers":null,"investors":"US-Israel Binational Industrial Research & Development (BIRD) Foundation","confidence":9,"key_topics":["On Demand Medicine Manufacturing","Drug Shortages","Supply Chain Risks","Pharmacy on Demand","Active Pharmaceutical Ingredients"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1M","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VhiOhAjS2CnIeY5fckEBSom0RrGOhuGNtUcFT25nlwt1oWXWqwktJE","news_summary":"On Demand Pharmaceuticals and Wavelength Pharmaceuticals Awarded BIRD Foundation Grant","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9f1a81ec-1539-48fe-b400-8d41cea3a32f","date":"Aug 17, 2021","link":"https://www.prnewswire.com/news-releases/tikun-olam-cannbit-continues-to-expand-its-footprint-in-the-pharmaceutical-arena-301355630.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"partnership","company":"Tikun-Olam Cannbit","layoffs":null,"summary":"Tikun-Olam Cannbit has entered into a partnership with Wavelength, an Israeli company that develops and exports active pharmaceutical ingredients (APIs) for the pharmaceutical industry. The partnership aims to jointly develop, manufacture, and market cannabis-based raw materials for the pharmaceutical industry. Wavelength, a portfolio company of SK Capital Partners, has a leading technology plant that operates in compliance with industry standards. The partnership is expected to target the global pharmaceutical market in light of regulatory changes regarding cannabis exports. This partnership signifies a step forward for Tikun-Olam Cannbit in the medical cannabis industry and the pharmaceutical sector.","partners":"Wavelength","customers":null,"investors":"SK Capital Partners","confidence":9,"key_topics":["partnership","pharmaceutical industry","cannabis-based raw materials","global pharmaceutical market","regulatory changes"],"date_of_event":"2021-08-16","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XmmTkXL6EGTqoOZiH3Niiwu0nyFxzSGcmJMFkHYSU4PH767nrrkHMX","news_summary":"Tikun olam-Cannbit continues to expand its footprint in the pharmaceutical arena","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"731336c0-c0b0-4c96-86b4-ac17ed0f5628","date":"Feb 18, 2021","link":"https://www.businesswire.com/news/home/20210218005123/en/Wavelength-Pharmaceuticals-Further-Strengthens-Its-Global-Supply-Chain-with-Acquisition-of-Vanamali-Organics","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"gazxlLob3F1migygZnLL96BtZjt75WZ9OHJSSVMYg93Cs0R0WaSKZD","news_summary":"Wavelength Pharmaceuticals Further Strengthens Its Global Supply Chain with Acquisition of Vanamali Organics","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9a09d35c-0425-4c05-9345-56bf5bc370b6","date":"Apr 20, 2020","link":"https://www.businesswire.com/news/home/20200420005073/en/Wavelength-Pharmaceuticals-Expands-Supplies-of-Key-Drug-Ingredients-for-Critically-Ill-COVID-19-Patients","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ekN5qiAAUhd3oxpz8WEs3dihWA4JyK0pFTEImvNutcnKeb9Yl6TBPI","news_summary":"Wavelength Pharmaceuticals Expands Supplies of Key Drug Ingredients for Critically Ill COVID-19 Patients","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c59bdc2a-4a7a-4c17-b891-e2d982bfc1e7","date":"Apr 20, 2020","link":"https://www.contractpharma.com/contents/view_breaking-news/2020-04-20/wavelength-ups-api-production-for-essential-respiratory-meds/","source":"www.contractpharma.com","visible":1,"analysis":{"tags":"Production Expansion, API CDMO Services","company":"Wavelength Pharmaceuticals","layoffs":"N/A","summary":"Wavelength Pharmaceuticals has expanded production of APIs for pharmaceuticals used to manage respiratory critical care patients due to the coronavirus pandemic. The company has also launched new API CDMO services that leverage its expertise in complex chemistry, crystalline forms, and particle design for the development and manufacturing of new APIs. The companys CEO, Iftach Seri, stated that their robust supply chain and regulatory track record have enabled them to quickly respond to the urgent need for life-saving care for critically ill COVID-19 patients.","partners":"N/A","customers":"Respiratory Critical Care Patients","investors":"N/A","confidence":9,"key_topics":"Coronavirus, Pharmaceuticals, Production Expansion, API CDMO Services, Respiratory Critical Care","date_of_event":"04.20.20","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QiG6bXQ8vvmBEAp3ubOBOihUY2jtwf6iSG7lSdEG1y6hBCxyyu2Qhz","news_summary":"Wavelength Ups API Production for Essential Respiratory Meds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"19a9cae9-6fcd-4918-b5bb-af3e3a1b91a5","date":"Nov 29, 2017","link":"https://www.businesswire.com/news/home/20171128006465/en/Wavelength-Pharmaceuticals-Names-Iftach-Seri-Chief-Executive","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"UsK8t4Tex1VHoYYHNuZ5GQeeFJ6e3Wgokvm6CFevQK58U6rAs4vo7V","news_summary":"Wavelength Pharmaceuticals Names Iftach Seri as Chief Executive Officer and Tami Cohen as Chief Financial Officer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"932d348f-c8b7-4804-ac7c-84948f32a1b1","date":"Nov 22, 2017","link":"http://en.globes.co.il/en/article-perrigo-completes-sale-of-israeli-unit-chemagis-for-110m-1001212804","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Perrigo Company","layoffs":null,"summary":"Perrigo Company has completed the sale of its Israel-based API unit Chemagis to SK Capital for $110 million. Perrigo API has been renamed Wavelength Pharmaceuticals. SK Capital has appointed four former Teva executives to its board of directors.","partners":null,"customers":null,"investors":"SK Capital","confidence":9,"key_topics":["Pharmaceutical company","Sale of Chemagis","SK Capital","Former Teva executives","Perrigo API renamed"],"date_of_event":"November 22, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":"$110 million","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6ANNDJNPRUJeFg1H8YIXrMhaDdUz4trM4nValeuK9wUnpL7BT8wV1m","news_summary":"Perrigo completes sale of Israeli unit Chemagis for $110m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4e8d3d19-616b-4e11-92ae-b21d88a4b091","date":"Aug 10, 2017","link":"https://en.globes.co.il/en/article-sk-capital-buys-perrigos-israel-unit-chemagis-for-110m-1001200794","source":"en.globes.co.il","visible":1,"analysis":{"tags":"pharmaceuticals, API unit, acquisition, sale","company":"Perrigo Company","layoffs":null,"summary":"Pharmaceutical company Perrigo has signed an agreement to sell its API unit Chemagis for $110 million to SK Capital. Perrigo acquired Chemagis in 2005 as part of a $818 million acquisition of Agis. Perrigo reported better than expected second quarter results, with revenue of $1.2 billion and a net loss of $70 million. The companys share price rose 12.7% on the Tel Aviv Stock Exchange. Perrigo is currently searching for a new CEO.","partners":null,"customers":null,"investors":"SK Capital","confidence":9,"key_topics":["Perrigo Company","Chemagis","SK Capital","API unit","sale"],"date_of_event":"August 10, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MIDMjOcGsWxL5PEawnK7SHYnBm1otwx9XWF3n3UCJ0r0BAlxFygDBr","news_summary":"SK Capital buys Perrigo's Israel unit Chemagis for $110m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":8,"techcommunityinvolvement":null,"mediagallery":[{"id":"zSVNkF9g60o5QwnAhDVYVt282D57abI0WhoBCmr2qEJdAuBCUJkkpx","timestamp":"2022-12-06 16:57:04.000000","resources_type":2,"resources_title":"","resources_file_name":"DQddruI-XDA","alt":"","imageurl":"https://img.youtube.com/vi/DQddruI-XDA/0.jpg","url":"http://youtu.be/DQddruI-XDA"},{"id":"0jysjAwdpE7KWGwvdk1KHe1VRAx8wkMX0cc86WTmkeTFACm6xM2cK8","timestamp":"2022-12-06 16:56:27.000000","resources_type":2,"resources_title":"","resources_file_name":"-qYKAqgqwE4","alt":"","imageurl":"https://img.youtube.com/vi/-qYKAqgqwE4/0.jpg","url":"http://youtu.be/-qYKAqgqwE4"}],"tags":["pharmaceuticals","api","allergy","sleep-disorders","gastroenterology","alzheimers-disease","supply-chain","respiratory","cancer","dermatology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["Granisetron Hydrochloride","Fexofenadine Hydrochloride"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Acquired","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Iftach  Seri","email":"iftach.seri@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNmq84kLDA","bounced":false,"claimed":0,"founder":0,"urlname":"iftach-seri","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg2Y7_nwkM","position":"CEO & Board Member","last_name":"Seri","claimtoken":"EFTjGobmHr6PnXppAGmdUFYmHjeAKUOf0Pw7otw4HQ7RjVqk4onbCf","first_name":"Iftach ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/iftach-seri-92565553","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-06 16:59:57.000000","initials":"IS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sarah  Isaacs","email":"sarah.isaacs@wavelengthpharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4JuXnI0KDA","bounced":false,"claimed":0,"founder":0,"urlname":"sarah-isaacs","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg26uFzwgM","position":"VP Quality, Regulatory & Compliance","last_name":"Isaacs","claimtoken":"532232d7dcc999b11017bae064fdce8e6c6cc9fff5a5b69c40267c0e4c7c50df","first_name":"Sarah ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-02-22 08:20:50.000000","initials":"SI","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Benzion  Dolitzky","email":"benzion.dolitzky@wavelengthpharma.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OuDy6ELDA","bounced":false,"claimed":0,"founder":0,"urlname":"benzion-dolitzky","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgm9WtzgsM","position":"VP R&D","last_name":"Dolitzky","claimtoken":"9y1OV5fzJY5gzCHkC4H7G60cIYIeNWN3XJGyKy9kMBicRHuh5mVdhF","first_name":"Benzion ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/benzion-dolitzky-b023b2112/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-06 17:02:29.000000","initials":"BD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Amit  Kalimi ","email":"amit.kalimi@wavelengthpharma.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ju2tvEJDA","bounced":false,"claimed":0,"founder":0,"urlname":"amit-kalimi","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgm7WK6QsM","position":"Head of Operations","last_name":"Kalimi ","claimtoken":"UWpwi7PukzMDLdXKAvVaRJGcHKEqN3P87Bk2QFUKnZ5M5Sbla8QJPj","first_name":"Amit ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/amit-kalimi-29951a160/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-06 17:02:16.000000","initials":"AK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2019-09-05T00:00:00.000Z","crunchbaseid":"perrigo-api","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yanina Wainscheinker","creator_email":"yanina.wain@gmail.com","createdate":"2018-06-18T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDSisjKCAw","date":"Jul 2022","amount":"Undisclosed","source":"https://www.calcalistech.com/ctechnews/article/skgah09oq","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"BIRD Foundation","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/bird-foundation-1","logokey":"$GlsX9ZAaRkNYGBNBNK2aPM2bDZqDo5fOQpyg5GcoLxx089Kc9vW9cM","tagline":null,"urlname":"/investor_page/bird-foundation-1","isisraeli":1,"investorid":"wkYw2Xa6wWAx2YsZ9ibCjlofkfLroUdqV57jv9Cfoi5vsESiKKOHLp","fundingtype":"Grant Provider","leadpartner":null,"investmentid":"uMf7tAYH6mv7Agj1AXaiYrO9ZdUS4yg9VihbvIXLQIn8feNAeVdWre","fundingsubtype":"Grant Provider","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$GlsX9ZAaRkNYGBNBNK2aPM2bDZqDo5fOQpyg5GcoLxx089Kc9vW9cM","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":1,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"oPGhgNfswAL1WGwDg9GBEq772U9SBFQ7mIG6xhpoqbZuGxztXk8ej5","date":"Dec 2021","amount":"Undisclosed","source":"https://www.chemanager-online.com/en/news/sk-capital-creates-new-cdmo-seqens-and-wavelength","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"SEQENS","acquiredcompany_mna_id":"ow9tYK1l3AmhYN8oqMtQuPLuUihgQnk3OTTZx8y2hxwGws3ybGCpLL","acquiredcompany_mna_type":"Multinational","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/mnc_page/seqens","acquiredcompany_mna_logokey":"$egzuzeSCl5mFFzZRhoOCP4EJTUEv7JWbNp5jqqra0Fr8Rz4K4k7G0a.jpeg","acquiredcompany_mna_urlname":"/mnc_page/seqens","acquiredcompany_mna_homepage":"https://www.seqens.com/","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$egzuzeSCl5mFFzZRhoOCP4EJTUEv7JWbNp5jqqra0Fr8Rz4K4k7G0a.jpeg","exit_label":"","po_label":"Public Offering","acquireddesc":"Merged to","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODr6taZCAw","date":"Feb 2021","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20210218005123/en/Wavelength-Pharmaceuticals-Further-Strengthens-Its-Global-Supply-Chain-with-Acquisition-of-Vanamali-Organics","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Vanamali Organics","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCrjvqACgw","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/vanamali-organics-1","acquiredcompany_mna_logokey":"$9dN6qBGSVX43eqvM1jB7lfNXEfKybUrMocbDOsZBSPvgFZDZDIUwGH","acquiredcompany_mna_urlname":"/company_page/vanamali-organics-1","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$9dN6qBGSVX43eqvM1jB7lfNXEfKybUrMocbDOsZBSPvgFZDZDIUwGH","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"T7ePnP0wE4JXV9gG1T70KAoQq3rgYVGrguQYZFuPjpYEXJQGReotZI","date":"Feb 2021","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20210218005123/en/Wavelength-Pharmaceuticals-Further-Strengthens-Its-Global-Supply-Chain-with-Acquisition-of-Vanamali-Organics","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Vanamali Organics","acquiredcompany_mna_id":"guW7WnfVt5XAQRI86eQnK1WrAk02VSapDLkdRtkvRkcpf93K2zxgbL","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/vanamali-organics","acquiredcompany_mna_logokey":"$uEWsBbFhDw7q7tVz1ke5TKGuq7VCjECtTQCFvUpIfRWPTq4Unz5ART","acquiredcompany_mna_urlname":"/company_page/vanamali-organics","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$uEWsBbFhDw7q7tVz1ke5TKGuq7VCjECtTQCFvUpIfRWPTq4Unz5ART","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkwKKkCAw","date":"Nov 2017","amount":"$110M","source":"Migrated","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"SK Capital Partners","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv97ECQw","acquiredcompany_mna_type":"Investor","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/investor_page/sk-capital-partners","acquiredcompany_mna_logokey":"$qNLav2cjIJET48MeHfRds1M6S6pE20U2u70dwiU9hSU1DFicGe5Xrz","acquiredcompany_mna_urlname":"/investor_page/sk-capital-partners","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$qNLav2cjIJET48MeHfRds1M6S6pE20U2u70dwiU9hSU1DFicGe5Xrz","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":110000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/1987","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Wavelength Pharmaceuticals","logourl":"https://storage.googleapis.com/clean-finder-353810/$03aYlHjRBU2hrkeSJ5ZsXYyBC2W1QXMFJuvHD2MRn5b102S3UevBhK","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$03aYlHjRBU2hrkeSJ5ZsXYyBC2W1QXMFJuvHD2MRn5b102S3UevBhK","seoabout":"Wavelength Pharmaceuticals develops and manufactures active pharmaceutical ingredients and select finished dosage forms.\r\n\r\nThe company focuses on differen...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances"},{"title":"Biologicals","key":"0-1","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Materials & Substances","Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"oPGhgNfswAL1WGwDg9GBEq772U9SBFQ7mIG6xhpoqbZuGxztXk8ej5","date":"Dec 2021","amount":"Undisclosed","source":"https://www.chemanager-online.com/en/news/sk-capital-creates-new-cdmo-seqens-and-wavelength","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"SEQENS","acquiredcompany_mna_id":"ow9tYK1l3AmhYN8oqMtQuPLuUihgQnk3OTTZx8y2hxwGws3ybGCpLL","acquiredcompany_mna_type":"Multinational","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/mnc_page/seqens","acquiredcompany_mna_logokey":"$egzuzeSCl5mFFzZRhoOCP4EJTUEv7JWbNp5jqqra0Fr8Rz4K4k7G0a.jpeg","acquiredcompany_mna_urlname":"/mnc_page/seqens","acquiredcompany_mna_homepage":"https://www.seqens.com/","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$egzuzeSCl5mFFzZRhoOCP4EJTUEv7JWbNp5jqqra0Fr8Rz4K4k7G0a.jpeg","exit_label":"","po_label":"Public Offering","acquireddesc":"Merged to","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkwKKkCAw","date":"Nov 2017","amount":"$110M","source":"Migrated","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"SK Capital Partners","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv97ECQw","acquiredcompany_mna_type":"Investor","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/investor_page/sk-capital-partners","acquiredcompany_mna_logokey":"$qNLav2cjIJET48MeHfRds1M6S6pE20U2u70dwiU9hSU1DFicGe5Xrz","acquiredcompany_mna_urlname":"/investor_page/sk-capital-partners","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$qNLav2cjIJET48MeHfRds1M6S6pE20U2u70dwiU9hSU1DFicGe5Xrz","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":110000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"privateequityfunding":[],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDSisjKCAw","date":"Jul 2022","amount":"Undisclosed","source":"https://www.calcalistech.com/ctechnews/article/skgah09oq","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"BIRD Foundation","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/bird-foundation-1","logokey":"$GlsX9ZAaRkNYGBNBNK2aPM2bDZqDo5fOQpyg5GcoLxx089Kc9vW9cM","tagline":null,"urlname":"/investor_page/bird-foundation-1","isisraeli":1,"investorid":"wkYw2Xa6wWAx2YsZ9ibCjlofkfLroUdqV57jv9Cfoi5vsESiKKOHLp","fundingtype":"Grant Provider","leadpartner":null,"investmentid":"uMf7tAYH6mv7Agj1AXaiYrO9ZdUS4yg9VihbvIXLQIn8feNAeVdWre","fundingsubtype":"Grant Provider","investorislead":1,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$GlsX9ZAaRkNYGBNBNK2aPM2bDZqDo5fOQpyg5GcoLxx089Kc9vW9cM","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":1,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODr6taZCAw","date":"Feb 2021","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20210218005123/en/Wavelength-Pharmaceuticals-Further-Strengthens-Its-Global-Supply-Chain-with-Acquisition-of-Vanamali-Organics","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Vanamali Organics","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCrjvqACgw","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/vanamali-organics-1","acquiredcompany_mna_logokey":"$9dN6qBGSVX43eqvM1jB7lfNXEfKybUrMocbDOsZBSPvgFZDZDIUwGH","acquiredcompany_mna_urlname":"/company_page/vanamali-organics-1","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$9dN6qBGSVX43eqvM1jB7lfNXEfKybUrMocbDOsZBSPvgFZDZDIUwGH","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"T7ePnP0wE4JXV9gG1T70KAoQq3rgYVGrguQYZFuPjpYEXJQGReotZI","date":"Feb 2021","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20210218005123/en/Wavelength-Pharmaceuticals-Further-Strengthens-Its-Global-Supply-Chain-with-Acquisition-of-Vanamali-Organics","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Vanamali Organics","acquiredcompany_mna_id":"guW7WnfVt5XAQRI86eQnK1WrAk02VSapDLkdRtkvRkcpf93K2zxgbL","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/vanamali-organics","acquiredcompany_mna_logokey":"$uEWsBbFhDw7q7tVz1ke5TKGuq7VCjECtTQCFvUpIfRWPTq4Unz5ART","acquiredcompany_mna_urlname":"/company_page/vanamali-organics","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$uEWsBbFhDw7q7tVz1ke5TKGuq7VCjECtTQCFvUpIfRWPTq4Unz5ART","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}